Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Hormone Therapy Clinical Trial

Official title: Hormone Therapy and Angiotensin-Dependent Arterial and Renal

Status Recruiting

Clinical Trial Summary

1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.

Clinical Trial Description

Participants are screened for eligibility. Study involves a 4.5 hour morning in the lab: 1. Participants come fasting 2. IV infusion and blood draws 3. Non invasive testing - Holter monitor, sphygmocor, bioelectrical impedance, blood pressure checks ;

Related Conditions & MeSH terms

• Hormone Therapy

• NCT number: NCT05442463
• Study type: Observational
• Source: University of Calgary
• Contact: Darlene Y Sola, BScN
• Phone: 4032107434
• Email: dsola@ucalgary.ca
• Status: Recruiting
• Start date: November 30, 2020
• Completion date: November 30, 2025